Pretreatment immunoscore and an inflamed tumor microenvironment (TME) are associated with efficacy in patients (Pts) with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel) in ZUMA-1

被引：7

作者：

Rossi, John M. ^{[1
]}

Galon, Jerome ^{[2
]}

Chang, Edmund ^{[1
]}

Perbost, Regis ^{[3
]}

Scholler, Nathalie ^{[1
]}

Turcan, Sarah ^{[3
]}

Danan, Corinne ^{[3
]}

Locke, Frederick L. ^{[4
]}

Neelapu, Sattva S. ^{[5
]}

Miklos, David B. ^{[6
]}

Jacobson, Caron A. ^{[7
]}

Lekakis, Lazaros J. ^{[8
]}

Lin, Yi ^{[9
]}

Ghobadi, Armin ^{[10
]}

Milletti, Francesca ^{[1
]}

Go, William Y. ^{[1
]}

Bot, Adrian ^{[1
]}

机构：

[1] Kite, Santa Monica, CA USA

[2] UPMC Univ Paris, Sorbonne Univ, Univ Paris Descartes, INSERM, Marseille, France

[3] HalioDx, Paris, France

[4] H Lee Moffitt Canc Ctr & Res Inst, Blood & Marrow Transplantat, Tampa, FL USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[6] Stanford Univ, Sch Med, Blood & Marrow Transplantat, Stanford, CA 94305 USA

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] Univ Miami Hlth Syst, Sylvester Comprehens Canc Ctr, Miami, FL USA

[9] Mayo Clin, Div Hematol, Rochester, MN USA

[10] Washington Univ, Sch Med, Div Med Oncol, St Louis, MO USA

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2019-CT153

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT153

引用

页数：3

共 50 条

[21] ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) plus Utomilumab Patients with Refractory Large B Cell Lymphoma
Reshef, Ran
Miklos, David B.
Timmerman, John M.
Jacobson, Caron A.
Bennani, Nabila N.
Rossi, John M.
Sherman, Marika
Zheng, Lianqing
Sun, Jennifer
Palluconi, Gabrielle
Kim, Jenny J.
Jain, Michael D.
BLOOD, 2019, 134
[22] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
Topp, Max S.
van Meerten, Tom
Hout, Roch
Minnema, Monique C.
Milpied, Noel
Lugtenburg, Pieternella J.
Thieblemont, Catherine
Wermke, Martin
Song, Kevin W.
Avivi, Irit
Kuruvilla, John
Duehrsen, Ulrich
Chu, Rong
Zheng, Lianqing
Plaks, Vicki
Kerber, Anne
Kersten, Marie Jose
MOLECULAR THERAPY, 2020, 28 (04) : 577 - 577
[23] Earlier Steroid Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 12 - 14
[24] 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma
Neelapu, Sattva S.
Ghobadi, Armin
Jacobson, Caron A.
Miklos, David B.
Lekakis, Lazaros J.
Oluwole, Olalekan O.
Lin, Yi
Braunschweig, Ira
Hill, Brian T.
Timmerman, John M.
Deol, Abhinav
Reagan, Patrick M.
Stiff, Patrick J.
Flinn, Ian W.
Farooq, Umar
Goy, Andre
McSweeney, Peter A.
Munoz, Javier
Siddiqi, Tanya
Chavez, Julio C.
Herrera, Alex F.
Xue, Allen
Jiang, Yizhou
Bot, Adrian
Rossi, John M.
Kim, Jenny J.
Go, William Y.
Locke, Frederick L.
BLOOD, 2018, 132
[25] 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma
Neelapu, Sattva S.
Ghobadi, Armin
Jacobson, Caron A.
Miklos, David B.
Lekakis, Lazaros J.
Oluwole, Olalekan
Lin, Yi
Braunschweig, Ira
Hill, Brian T.
Timmerman, John
Deol, Abhinav
Reagan, Patrick M.
Stiff, Patrick
Flinn, Ian W.
Farooq, Umar
Goy, Andre
McSweeney, Peter A.
Munoz, Javier
Siddiqi, Tanya
Chavez, Julio C.
Herrera, Alex F.
Xue, Allen
Jiang, Yizhou
Bot, Adrian
Rossi, John M.
Kim, Jenny J.
Go, William Y.
Locke, Frederick L.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
[26] 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma
Zhang, Muchen
Fang, Ying
Xu, Pengpeng
Cheng, Shu
Wang, Li
Zhao, Wei-Li
BLOOD, 2018, 132
[27] A standardized comparison of outcomes in patients (pts) with refractory, aggressive non-hodgkin Lymphoma (rNHL) from the SCHOLAR-1 analysis and the ZUMA-1 study of axicabtagene ciloleucel (axi-cel)
Neelapu, S. S.
Locke, F. L.
Bartlett, N. L.
Lekakis, L. J.
Reagan, P. M.
Miklos, D.
Jacobson, C. A.
Braunschweig, I.
Oluwole, O.
Siddiqi, T.
Lin, Y.
Crump, M.
Kuruvilla, J.
Van den Neste, E.
Link, B. K.
Farooq, U.
Navale, L.
Go, W. Y.
Wiezorek, J.
Gisselbrecht, C.
ANNALS OF ONCOLOGY, 2017, 28
[28] Preliminary results of earlier steroid use with axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory large B cell lymphoma
Topp, M. S.
van Meerten, T.
Wermke, M.
Lugtenburg, P. J.
Minnema, M. C.
Song, K. W.
Thieblemont, C.
Jiang, Y.
Plaks, V
Kerber, A.
Kersten, M. J.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 65 - 66
[29] Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)
Jacobson, Caron
Locke, Frederick L.
Ghobadi, Armin
Miklos, David B.
Lekakis, Lazaros J.
Oluwole, Olalekan O.
Lin, Yi
Braunschweig, Ira
Hill, Brian T.
Timmerman, John M.
Deol, Abhinav
Reagan, Patrick M.
Stiff, Patrick J.
Flinn, Ian W.
Farooq, Umar
Goy, Andre H.
McSweeney, Peter A.
Munoz, Javier
Siddiqi, Tanya
Rossi, John M.
Bot, Adrian
Zheng, Lianqing
Vezan, Remus
Bashir, Zahid
Kim, Jenny J.
Chu, Rong
Neelapu, Sattva S.
BLOOD, 2020, 136
[30] Phase 1/2 primary analysis of ZUMA-6: Axicabtagene ciloleucel (Axi-Cel) in combination With atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL)
Jacobson, Caron A.
Westin, Jason R.
Miklos, David B.
Herrera, Alex F.
Lee, Jennifer
Seng, Judy
Rossi, John M.
Sun, Jennifer
Dong, Jinghui
Roberts, Zachary J.
Vezan, Remus
Avanzi, Mauro P.
Locke, Frederick L.
CANCER RESEARCH, 2020, 80 (16)

← 1 2 3 4 5 →